On December 4, 2023, Nanobiotix S.A. closed the transaction. The company issued 901,256 additional ordinary shares of the Company, in the form of restricted American Depositary Shares at a price $5.36 for a gross proceeds $4,830,732.16 in its second and final tranche, the company has issued total 4,664,179 shares for total gross proceeds of $24,999,999.44 in the transaction.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.17 EUR | +0.82% | -6.09% | -7.08% |
May. 22 | Nanobiotix: strategy update, share price declines | CF |
May. 21 | Nanobiotix to Transfer Phase 3 Head and Neck Cancer Study Sponsorship | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-7.08% | 313M | |
+67.53% | 63.85B | |
-0.77% | 41.83B | |
+44.98% | 40.65B | |
-10.87% | 27.12B | |
+13.30% | 26.52B | |
-22.79% | 18.69B | |
+4.70% | 12.73B | |
+24.10% | 12.11B | |
+27.41% | 12.07B |
- Stock Market
- Equities
- NANO Stock
- News Nanobiotix
- Nanobiotix S.A. announced that it has received $24.999999 million in funding from Johnson & Johnson Innovation - JJDC, Inc.